Changchun GeneScience Pharmaceutical Co., Ltd.: all 111 studies
Page 2 of 2. Open to participants first (48), then studies with results posted, then the rest; newest registration first within each.
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyStatus unknownNCT02908958Phase 4
- Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ETStatus unknownNCT02801591
- Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOSStatus unknownNCT02801565Not applicable
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)Status unknownNCT02380235Phase 4
- Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short StatureActive, not recruitingNCT02375620Phase 2
- Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II AnovulationCompletedNCT02335879Phase 3
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknownNCT02314676Phase 4
- Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness BurnCompletedNCT01785784Phase 4
- Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD ChildrenCompletedNCT01613573Phase 1
- Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenCompletedNCT01495468Phase 3
- Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency ChildrenCompletedNCT01342146Phase 2
← Changchun GeneScience Pharmaceutical Co., Ltd. overview and focus areas